Recombinant super-compound interferon and uses thereof

Abstract

This invention provides a method for treating upper respiratory tract infection in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the recombinant interferon has the amino acid sequence of SEQ ID NO:1 and is encoded by the nucleotide sequence SEQ ID NO:2. The upper respiratory tract infection can be induced by various viruses such as rhinovirus, coronavirus, respiratory syncytial virus, influenza, parainfluenza, adenoviruses, coxsackie virus, corona virus and enterovirus.

1 - 77 . (canceled) 
     
     
         78 . A method for treating an upper respiratory tract infection in a subject, comprising administering to the subject an effective amount of a recombinant interferon, wherein the recombinant interferon has the amino acid sequence of SEQ ID NO:1 and is encoded by the nucleotide sequence SEQ ID NO:2. 
     
     
         79 . The method of  claim 78 , wherein the recombinant interferon is produced by a method comprising the step of expressing SEQ ID NO:2 in  E. coli  host cells. 
     
     
         80 . The method of  claim 78 , wherein the upper respiratory tract infection is induced by a virus selected from the group consisting of rhinovirus, coronavirus, respiratory syncytial virus, influenza, parainfluenza, adenoviruses, cox-sackie virus, corona virus and enterovirus. 
     
     
         81 . The method of  claim 78 , wherein the effective amount of the recombinant interferon comprises a dose in a range from nanogram to microgram. 
     
     
         82 . The method of  claim 78 , wherein the recombinant interferon is administered orally, via vein injection, muscle injection, peritoneal injection, subcutaneous injection, nasal or mucosal administration, or by inhalation. 
     
     
         83 . The method of  claim 78 , wherein the recombinant interferon is administered to the subject by spraying the recombinant interferon directly to the subject's nasal cavity or throat. 
     
     
         84 . The method of  claim 78 , wherein the recombinant interferon is administered via a spray device containing twenty micrograms of the recombinant interferon in three millilitres three times a day. 
     
     
         85 . The method of  claim 78 , wherein the recombinant interferon is administered following a protocol of 9 μg, 15 μg or 24 μg injection per day, 3 times a week, for a total of 24 weeks. 
     
     
         86 . The method of  claim 78 , wherein the subject has one or more symptoms selected from the group consisting of malaise, nasal stuffiness, rhinorrhea, nonproductive cough, mild sore throat and low-grade fever. 
     
     
         87 . The method of  claim 78 , wherein the recombinant interferon modulates one or more immune responses in the subject, said immune responses are selected from the group consisting of T-cell immune response, activity of natural killer cell, phagocytosis function of monokaryon and formation of antibodies. 
     
     
         88 . A spray device for administering a recombinant interferon to a subject for treating an upper respiratory tract infection, comprising an effective amount of the recombinant interferon, wherein the recombinant interferon has the amino acid sequence of SEQ ID NO:1 and is encoded by the nucleotide sequence SEQ ID NO:2. 
     
     
         89 . The spray device of  claim 88 , wherein the recombinant interferon is produced by a method comprising the step of expressing SEQ ID NO:2 in  E. coli  host cells. 
     
     
         90 . The spray device of  claim 88 , wherein the recombinant interferon is formulated at a concentration of 10 μg/ml. 
     
     
         91 . The spray device of  claim 88 , wherein the effective amount of the recombinant interferon comprises a dose in a range from nanogram to microgram. 
     
     
         92 . The spray device of  claim 88 , containing twenty micrograms of the recombinant interferon. 
     
     
         93 . The spray device of  claim 92 , wherein the recombinant interferon is formulated in a volume of three milliliters. 
     
     
         94 . The spray device of  claim 88 , wherein the recombinant interferon is formulated in an amount for administering the recombinant interferon three times a day. 
     
     
         95 . The spray device of  claim 88 , wherein the recombinant interferon is administered to the subject by spraying the recombinant interferon directly to the subject's nasal cavity or throat.